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Background: Enhanced EGF receptor (EGFR) signaling is a hallmark of many human cancers, though the role of
enhanced EGFR signaling within the surrounding tumor stroma has not been well studied. The myofibroblast is an
important stromal cell that demonstrates enhanced EGFR expression in the setting of inflammation, though the
functional relevance is not known. We recently reported that TNF-α and the G protein-coupled receptor (GPCR)
agonist lysophosphatidic acid (LPA) lead to synergistic cyclo-oxygenase-2 (COX-2) expression, an enzyme strongly
associated with the development of colitis-associated cancer. Here, we investigate whether EGFR signaling plays a
role in the synergistic COX-2 expression induced by LPA and TNF-α.
Methods: 18Co cells, a model of human colonic myofibroblasts, were grown to confluence on 35 × 10mm cell
culture dishes and were used from passages 10–14. 18Co cells were treated with TNF-α (8.3 ng/ml) and LPA
(10 μM). EGFR and COX-2 protein expression, Y1068 phosphorylation, and p42/44 MAPK phosphorylation were
assessed by Western Blot, in the presence and absence of various inhibitors.
Results: Exposure of 18Co cells to either TNF-α or LPA alone had no effect on EGFR autophosphorylation at Y1068.
However, chronic exposure to TNF-α led to upregulation of EGFR in association with sustained LPA-mediated EGFR
phosphorylation at Y1068. TNF-α and LPA also led to sustained p42/44 MAPK phosphorylation and synergistic
COX-2 expression, effects that were partially inhibited by the EGFR tyrosine kinase inhibitor AG1478. p42/44 MAPK
phosphorylation and COX-2 expression were inhibited to the same degree by the MMP inhibitors GM6001 and
BB-94, suggesting that LPA-mediated EGFR transactivation involved MMP-mediated release of EGFR ligands from
the cell surface. The Src inhibitor SU6556 inhibited TNF-α/LPA-mediated EGFR phosphorylation at Y1068, p42/44
MAPK phosphorylation, and COX-2 expression in a dose-dependent fashion, suggesting an upstream role of Src in
the transactivation of EGFR.
Conclusion: Synergistic COX-2 expression induced by TNF-α and LPA involves Src/MMP-mediated transactivation of
EGFR and downstream p42/44 MAPK activation in human colonic myofibroblasts. Enhanced EGFR expression
induced by TNF-α promotes GPCR-mediated EGFR transactivation in colonic myofibroblasts, providing an important
mechanism for stromal COX-2 over-expression that may predispose to the development of colitis-associated cancer.
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Myofibroblasts are an influential stromal subpopulation
that interact with neighboring cells in a paracrine
fashion to regulate a number of important cellular
processes, including intestinal epithelial proliferation
and differentiation along the crypt-villous axis, mucosal
repair, and fibrosis [1]. They also participate in immune
and inflammatory responses and have been implicated in
the pathophysiology of inflammatory bowel disease
(IBD) and colitis-associated cancer [2,3].
Myofibroblasts are a target of inflammatory mediator
signaling and, in particular, TNF-α, a 17-kDa pro-
inflammatory cytokine that has been implicated in the
pathogenesis of colitis-associated cancer [4,5]. TNF-α is
found in high concentrations in the lamina propria of
patients with ulcerative colitis [6], which is where
myofibroblasts reside, and is known to regulate the
signaling pathways that govern their function [7,8].
TNF-α binds to its receptors, TNF-α receptor 1
(TNFR1) and TNF-α receptor 2 (TNFR2), triggering the
formation of a multiprotein complex (TRADD, RIP,
TRAF-2) that culminates in the activation of MAP
kinases and the transcription factor NFκB [reviewed in
[9]]. However, alternative cross talk mechanisms exist
between TNF-α and other pro-inflammatory mediators,
including multiple G protein-coupled receptor (GPCR)-
mediated agonists [7,8], that not only sustain the chronic
inflammation associated with IBD, but also trigger a
counter-regulatory response intended to promote mucosal
healing. Chronic inflammation leads to the upregulation of
cyclo-oxygenase-2 (COX-2), also known as prostaglandin-
endoperoxide synthase 2, which is encoded by the PTGS2
gene in humans. COX-2, the rate-limiting enzyme in the
biosynthesis of prostaglandins (PGs) and thromboxanes, is
one example of a cytoprotective response to mucosal injury
that, when dysregulated, may promote epithelial trans-
formation to an invasive phenotype and the development
of cancer [8,10]. It is increasingly recognized that the stro-
mal compartment is the major reservoir of COX-2 in the
GI tract [11,12]. Therefore, the regulation of COX-2
expression in the colonic myofibroblast may be highly
relevant to the pathogenesis of inflammation-associated
cancer in the gut.
We recently reported that TNF-α dramatically upre-
gulates epidermal growth factor receptor (EGFR) expres-
sion on the cell surface of colonic myofibroblasts [11],
though the functional significance of this upregulated
expression is not fully known. Here, we demonstrate, for
the first time, that enhanced EGFR expression induced
by TNF-α facilitates GPCR-mediated EGFR transactiva-
tion in colonic myofibroblasts, providing an important
mechanism for stromal COX-2 over-expression that may
predispose to the development of colitis-associated
cancer.Methods
Cell culture
18Co cells (CRL-1459) were purchased from American
Type Culture Collection (Rockville, MD). These cells
share structural and functional characteristics of in situ
colonic myofibroblasts, including a reversible stellate
morphology, α-smooth muscle actin (α-SMA) expression
and the presence of multiple cell surface receptors [13].
18Co cells were maintained at 37°C in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum in a humidified atmosphere con-
taining 10% CO2 and 90% air. Cells were plated in
35 mm dishes (1 × 105 cells/dish) and grown in DMEM
containing 10% fetal bovine serum for 5–7 days until
confluent, and used from passages 8–14.
Western blot
Confluent 18Co cells, treated as indicated in the individual
experiments, were lysed in 2× SDS-polyacrylamide gel
electrophoresis (PAGE) sample buffer (20 mM Tris/HCl,
pH 6.8, 6% SDS, 2 mM EDTA, 4% 2-mercaptoethanol,
10% glycerol) and boiled for 10 min. After SDS-PAGE,
proteins were transferred to Immobilon-P membranes.
The transfer was carried out at 100 V, 0.4A at 4°C for 5 h
using a Bio-Rad transfer apparatus. The transfer buffer
consisted of 200 mM glycine, 25 mM Tris, 0.01% SDS,
and 20% CH3OH. Membranes were blocked and then
incubated for 2 h with the desired antibodies diluted
in PBS (pH 7.2) containing 3% nonfat dried milk.
Primary antibodies bound to immunoreactive bands
were visualized by enhanced chemiluminescence (ECL)
detection with horseradish peroxidase-conjugated anti-
mouse or anti-rabbit antibodies (GE Healthcare,
Piscataway, NJ).
Myofibroblast isolation
A protocol to obtain human tissue from surgical patients
was approved by the UCLA Office of Human Research
Protection Program (IRB #11-000337). Participation in
this study involved obtaining written informed consent.
Human colon tissue immediately taken from surgically
resected colon was washed with ice cold sterile PBS and
then shaken 5× for 15 min in HBSS containing 5 mM
EDTA. Next, the tissue was incubated in 20 ml of
RPMI-5 [RPMI with 5% FCS, 10 mM HEPES, 2 mM L-
glutamine, 1 mM sodium pyruvate, 100 U/ml Pen-Strep]
containing 10.5 mg of Dispase (GIBCO-Invitrogen,
Carlsbad, CA) and 7.2 mg of collagenase D (Roche
Diagnostics, Indianapolis, IN) for 2 h in a shaking
37°C incubator. The digested tissue was treated with
ACK lysis buffer for 5 min, and then was passed
through a 70-μM cell strainer into 100-mm dishes in
RPMI-5. After a 3 h incubation, nonadherent cells
were washed away, leaving adherent cells consisting
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several days, macrophages died off leaving cells with a
myofibroblast phenotype that were consistently α-
SMA and vimentin positive. Primary colonic myofi-
broblast cultures were used for experiments up to
passage 4.Materials
TNF-α was purchased from R&D Systems (Minneapolis,
MN). α-SMA antibody (1:1000, ab5694) was purchased
from Abcam (Cambridge, MA). EGFR antibody (1:1000,
#2232), Y1068 antibody (1:1000, #2234) and p42/44 MAPK
antibody (1:1000, #9106) were purchased from Cell Signal-
ing Technology (Danvers, MA). COX-2 antibody (1:1000,
#160106) and LPA were purchased from Caymann Che-
mical (Ann Arbor, MI). GM6001, SU6556, and AG1478
were purchased from Calbiochem (Gibbstown, NJ). BB-94
was purchased from Tocris (Bristol, United Kingdom). EGF
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Figure 1 TNF-α Potentiates LPA-mediated EGFR Phosphorylation at Y
various times (broken lines), with or without pre-incubation with 10 ng/ml
with antibodies that detect EGFR and EGFR phosphorylation at Y1068. Den
percentage of the maximal level of EGFR Y1068 phosphorylation. In all exp
Panel B: 18Co cells were incubated with EGF (5 ng/ml) for 5 or 60 min (bro
18 h (indicated by solid line). Western blot analysis used an antibody detec
three separate experiments. Panel C: 18Co cells were exposed to 10 μM LP
TNF-α for 18 h (indicated by solid line). Western blot analysis detected COX
mean ± S.E. (n ≥ 3), expressed as a percentage of the maximal level of p42/Results and discussion
TNF-α potentiates LPA-mediated EGFR phosphorylation at
Y1068
To determine whether chronic exposure to TNF-α
affects LPA-mediated transactivation of EGFR, 18Co
cells were stimulated with LPA over 4 h, with or without
a prior treatment with TNF-α for 18 h. EGFR auto-
phosphorylation was monitored by Western blot analysis
using an antibody that detects the phosphorylated state
of the residue Y1068. In cells exposed to LPA alone,
there was no detectable phosphorylation of EGFR at
Y1068 (Figure 1A). In contrast, 18Co cells treated with
TNF-α for 18 h displayed a striking increase in EGFR
phosphorylation at Y1068, which correlated with an
upward shift of the EGFR band. LPA-induced EGFR
phosphorylation was rapid (evident after 5 min of stimu-
lation) and sustained since it remained elevated over the
4 h time period. 18Co cells treated with TNF-α for 18 h
displayed a marked increase in EGFR protein expression,
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1068. Panel A: Confluent 18Co cells were exposed to 10 μM LPA for
TNF-α for 18 h (indicated by solid line). Western blot analysis was used
sitometry analysis shows the mean ± S.E. (n ≥ 3), expressed as
eriments, equal protein loading was verified using α-SMA antibody.
ken lines), with or without pre-incubation with 10 ng/ml TNF-α for
ting EGFR phosphorylation at Y1068. The results are representative of
A for 8 h (broken lines), without or with pre-incubation with 10 ng/ml
-2 and p42/44 MAPK phosphorylation. The results shown are the
44 MAPK phosphorylation, displayed graphically on the right.
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pared to 18Co cells that were exposed to EGF (5 ng/ml),
a direct EGFR ligand, with or without a prior incubation
with TNF-α for 18 h (Figure 1B). Stimulation of 18Co
cells with EGF alone led to a rapid and transient
phosphorylation of EGFR at Y1068, returning close to
baseline levels after 1 h. Pre-incubation with TNF-α for
18 h followed by exposure to EGF enhanced the signal
intensity of Y1068 phosphorylation, consistent with
increased EGFR protein expression, but did not signifi-
cantly alter the time course, with a sharp decline in
Y1068 phosphorylation levels at 1 h. These results
demonstrate that while chronic exposure to TNF-α
potentiates both EGF- and LPA-mediated EGFR
phosphorylation at Y1068, the pattern of phosphoryl-
ation is strikingly different, with LPA producing a less
pronounced but more sustained EGFR phosphorylation
compared to that induced by direct ligand binding
by EGF.Enhanced p42/44 MAPK phosphorylation and COX-2
expression induced by TNF-α and LPA are partially
inhibited by AG1478
The sustained level of phosphorylation of EGFR induced
by treatment with TNF-α and LPA suggested a potential
role in long-term processes such as the regulation of
COX-2 [8]. Stimulation of 18Co cells with LPA after
treatment with TNF-α produced a synergistic time-
dependent increase in COX-2 protein expression that
was evident after 2 h and steadily increases over 8 h
(Figure 1C), consistent with previous reports [8]. To
determine whether p42/44 MAPK, a known down-
stream signaling target of both LPA and the EGFR, is
involved in mediating this response, p42/44 MAPK
phosphorylation was also analyzed by Western blot.
Exposure of 18Co cells to LPA alone led to rapid and
transient p42/44 MAPK phosphorylation, evident after
2.5 min with a return to baseline levels after 15 min, as
shown in Figure 1C. However, in cells exposed to both
TNF-α and LPA, there was a striking increase in the
duration of p42/44 MAPK phosphorylation that was
evident at 15 min and was sustained over 8 h. These
results demonstrate that TNF-α and LPA stimulate
synergistic COX-2 expression that is associated with
enhanced p42/44 MAPK phosphorylation in human
colonic myofibroblasts.
In order to evaluate a possible role of EGFR in the
synergistic expression of COX-2 in response to LPA
and TNF-α, 18Co cells were pre-incubated with the
EGFR tyrosine kinase inhibitor AG1478 for 1 h prior to
exposure to LPA with or without TNF-α. Cells exposed
to TNF-α and LPA demonstrated enhanced COX-2
expression and p42/44 MAPK phosphorylation, aspreviously described (Figure 2A). AG1478 partially
inhibited both p42/44 MAPK phosphorylation and
COX-2 expression, suggesting that the EGFR and the
downstream signaling target p42/44 MAPK were both
involved in this response.
To confirm specificity for EGFR, 18Co cells were also
pre-incubated with AG1478 and then exposed to EGF,
which only binds to this receptor, with or without TNF-
α. As anticipated, AG1478 inhibited EGF-mediated
COX-2 expression and p42/44 MAPK phosphorylation
to baseline levels (Figure 2A). Importantly, AG1478 did
not inhibit COX-2 expression induced by TNF-α alone,
suggesting that EGFR transactivation was not involved
in TNF-α-mediated COX-2 expression. The data indi-
cates that the maximal expression of COX-2 protein in
response to TNF-α and LPA requires EGFR kinase
activity.p42/44 MAPK phosphorylation and COX-2 expression
induced by TNF-α and LPA are partially inhibited by MMP
inhibitors
A potential mechanism for GPCR-induced EGFR transac-
tivation involves matrix metalloproteinase (MMP)-acti-
vated release of extracellular ligands by the a disintegrin
and metalloprotease (ADAM) family [14]. To test for the
involvement of MMP’s in the expression of COX-2
induced by TNF-α and LPA, 18Co cells were treated
with TNF-α and LPA in the presence or absence of the
broad-spectrum MMP inhibitors GM6001 and BB-94,
which inhibit multiple MMP’s and ADAMs. Both
BB-94 and GM6001 partially inhibited COX-2 expres-
sion, and to the same degree as AG1478, suggesting
that transactivation of EGFR was MMP-mediated
(Figure 2B). The consistent findings seen with two
different MMP inhibitors implies that the inhibitory
effects were not due to off target effects. Accordingly,
GM6001 and BB-94 did not inhibit COX-2 expression
and p42/44 MAPK phosphorylation induced by TNF-α
and EGF (Figure 2C).
The Src inhibitor SU6556 partially inhibits EGFR
phosphorylation at Y1068, p42/44 MAPK activation, and
COX-2 Expression
In some systems, MMP-induced EGFR transactivation
involves Src, a non-receptor tyrosine kinase that has
been implicated in EGFR phosphorylation [15]. To test
for a role of Src in the transactivation of EGFR, 18Co
cells were treated with TNF-α and LPA in the presence
or absence of the Src inhibitor Su6556 at various
concentrations. As demonstrated in Figure 3A, pre-
treatment with SU6656 prevented Y1068 phosphory-
lation induced by TNF-α and LPA in a dose-dependent









































































































































































































Figure 2 Enhanced p42/44 MAPK phosphorylation and COX-2 expression induced by TNF-α and LPA are partially inhibited by AG1478
and MMP inhibitors. Panel A: 18Co cells were pre-treated with 1 μM AG1478 for 1 h and then 5 ng/ml EGF or 10 μM LPA with or without pre-
incubation with 10 ng/ml TNF-α for 18 h. Western blot analysis detected COX-2 and p42/44 MAPK phosphorylation. The results shown are the
mean ± S.E. (n ≥ 3), expressed as a percentage of the maximal level of COX-2 expression and p42/44 MAPK phosphorylation, displayed graphically
on the right. For all experiments, * denotes statistical significance, p < 0.05. Panel B: 18Co cells were incubated with or without 10 ng/ml TNF-α
for 18 h, followed by 10 μM LPA for 4 h with or without pre-treatment with 1 μM AG1478, 10 μM GM6001, or 5 μM BB-94 for 1 h. The results
shown are the mean ± S.E. (n ≥ 3), expressed as a percentage of the maximal level of COX-2 expression and p42/44 MAPK phosphorylation,
displayed graphically on the right. Panel C: 18Co cells were incubated with or without 10 ng/ml TNF-α for 18 h, followed by exposure to 5 ng/ml
EGF for 4 h with or without pre-treatment with 1 μM AG1478, 10 μM GM6001, or 5 μM BB-94 for 1 h. The results are representative of three
separate experiments.
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SU6556 followed by treatment with TNF-α and LPA.
SU6656 inhibited p42/44 MAPK phosphorylation and
COX-2 expression at levels that correlated to the degree
of inhibition induced by AG1478, GM6001, and BB-94
(Figure 3B). To verify that SU6556 was not directly
inhibiting EGFR auto-phosphorylation, 18Co cells were
also treated with EGF and Y1068 phosphorylation was
analyzed by Western blot. SU6556 did not inhibit EGF-
induced EGFR phosphorylation (data not shown),
suggesting that the inhibitory effects of SU6556 were
not due to non-specific inhibition of EGFR. These
results indicate that the full expression of COX-2 pro-
tein induced by TNF-α and LPA is partially mediated
through Src-dependent transactivation of EGFR viaMMP’s that result in downstream activation of p42/44
MAPK.
Synergistic COX-2 expression induced by TNF-α and LPA
involves EGFR Transactivation in Primary Human Colonic
Myofibroblasts
To confirm that EGFR transactivation contributes to the
enhanced expression of COX-2 induced by LPA and
TNF-α is relevant and reproducible in early passage
cultures of human cells, colonic myofibroblasts were
isolated from surgically resected human colon tissue
using a well-established protocol for myofibroblast iso-
lation [16]. Isolated cells demonstrated a myofibroblast-
like phenotype that was consistently α-SMA and
vimentin positive [11]. As shown in Figure 4A, human
COX-2
-SMA
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Figure 4 Synergistic COX-2 expression induced by TNF-α and LPA involves EGFR Transactivation in Primary Human Colonic
Myofibroblasts. Panel A: Cell lysates of primary colonic myofibroblasts isolated from human colon tissue were incubated with 10 ng/ml TNF-α,
10 μM LPA, or both for 24 h. Western blot analysis used an antibody that detects COX-2. Densitometry analysis is presented as mean ± S.E. (n ≥ 3).
Panel B: Primary colonic myofibroblasts were incubated with or without 10 ng/ml TNF-α for 18 h, then with AG1478 for 1 h followed by 10 μM











































































































































Figure 3 The Src inhibitor SU6556 partially inhibits EGFR phosphorylation at Y1068, p42/44 MAPK activation, and COX-2 Expression.
Panel A: 18Co cells were incubated with or without 10 ng/ml TNF-α for 18 h, then were pre-treated with SU6556 for 1 h at the indicated
concentrations, followed by 10 μM LPA for 4 h. The results are representative of three separate experiments. Panel B: 18Co cells were incubated
for 18 h with or without 10 ng/ml TNF-α, then 250 nM SU6556 for 1 h followed by LPA for 4 h. Densitometry analysis is presented as mean ± S.E.,
(n≥ 3), expressed as a percentage of the maximal level of COX-2 and p42/44 MAPK phosphorylation, depicted graphically on the right.
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displayed a time-dependent increase in COX-2 expres-
sion over 24 h. Pre-incubation with AG1478 prior to
exposure to LPA and TNF-α partially inhibited COX-2
expression (Figure 4B), supporting the contribution of
EGFR transactivation in the enhanced expression of
COX-2 by LPA and TNF-α in human primary cells.Conclusion
Myofibroblasts, TNF-α, LPA, EGFR, and COX-2 have all
been strongly and independently implicated in the devel-
opment of colorectal cancer [10,17-19]. This study
describes a novel interaction (Figure 5) that links
myofibroblasts with these mediators and may partially
explain how cross talk interactions initiated by TNF-α
may incite both an inflammatory and a cytoprotective re-
sponse that predisposes to colitis-associated cancer. The
present study supports the notion that TNF-α utilizes
EGFR signaling to mediate physiologic effects [11,20], and
raises the possibility that targeted inhibition of one path-
way may influence the biologic function of the other.
Given the critical importance of TNF-α and EGF on intes-
tinal inflammation, mucosal repair, and the development
of cancer, the identification of signaling interactions
between them may provide invaluable insight in the











Figure 5 LPA-mediated transactivation of upregulated EGFR enhance
demonstrated that TNF-α potentiates LPA-mediated COX-2 expression via P
signaling in human colonic myofibroblasts [11]. Here, we demonstrate cros
transactivation of upregulated EGFR, leading to enhanced COX-2 expressio
illustrated in graphical form.Furthermore, mounting evidence supports a causal
relationship between LPA-mediated signaling and can-
cer progression [21], particularly in the context of
colitis-associated cancer [22]. This connection was
reinforced by the discovery that autotaxin, an enzyme
known to promote tumor invasion and metastasis, acts
by producing LPA in the tumor microenvironment
[17]. LPA has been linked to a variety of cancers,
including colorectal cancer [22-24], as well as to the
production of COX-2 and prostaglandin secretion
[22,25] by stromal cells of the gastrointestinal tract
[26]. In a similar fashion, aberrant activation of EGFR
signaling has been implicated in the development and
progression of many human cancers [27-29]. The
results presented here identify a novel mechanism of
cross talk involving LPA and TNF-α which stimulates
EGFR signaling and COX-2 expression, through
LPA-induced transactivation in myofibroblasts. Future
investigations will also evaluate potential cross talk
mechanisms between TNF-α, LPA, and EGFR in
the regulation of COX-1. Enhanced EGFR signaling
within the intestinal stroma may play an impor-
tant role in the development and progression of
inflammation-associated cancer. The upregulation of
EGFR signaling within the tumor stroma deserves















s COX-2 expression in colonic myofibroblasts. We have previously
KD [8], and that TNF-α induces upregulation of EGFR expression and
s talk between these two signaling pathways through LPA-mediated
n in colonic myofibroblasts. A summary of the signaling interactions is
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